Symbol="LYEL"
AssetType="Common Stock"
Name="Lyell Immunopharma Inc"
Description="Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington."
CIK="1806952"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="554770000"
EBITDA="-189482000"
PERatio="None"
PEGRatio="None"
BookValue="2.935"
DividendPerShare="0"
DividendYield="0"
EPS="-0.83"
RevenuePerShareTTM="0.194"
ProfitMargin="0"
OperatingMarginTTM="-4.316"
ReturnOnAssetsTTM="-0.141"
ReturnOnEquityTTM="-0.261"
RevenueTTM="48481000"
GrossProfitTTM="84683000"
DilutedEPSTTM="-0.83"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.999"
AnalystTargetPrice="7.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="20.91"
PriceToBookRatio="1.066"
EVToRevenue="7.42"
EVToEBITDA="-1.436"
Beta="-1.432"
num_52WeekHigh="8.74"
num_52WeekLow="1.77"
num_50DayMovingAverage="2.915"
num_200DayMovingAverage="3.017"
SharesOutstanding="251027000"
DividendDate="None"
ExDividendDate="None"
symbol="LYEL"
open="2.22"
high="2.28"
low="2.09"
price="2.17"
volume="338796.00"
latest_trading_day="2023-08-22"
previous_close="2.21"
change="-0.04"
change_percent="-1.8100%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="43"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="57"
Volume_recent_avg="994817"
Change_recent_avg="0.01"
Delta_recent_avg="0.24"
Variance_recent_avg="0.12"
Change_ratio_recent_avg="-0.3"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="57"
Aroon_momentum_negative="43"
image_negative_thumbnail_id_1="488"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0117.jpeg"
image_negative_thumbnail_id_2="518"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0087.jpeg"
image_neutral_thumbnail_id_1="589"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0010.jpeg"
image_neutral_thumbnail_id_2="561"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0038.jpeg"
image_positive_thumbnail_id_1="993"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0155.jpeg"
image_positive_thumbnail_id_2="964"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0126.jpeg"
image_professor_thumbnail_id_1="1180"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
image_professor_thumbnail_id_2="1178"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
